ERBB2 and breast carcinoma: The findings of this study are consistent with recent data from the phase III JBCRG-M06/EMERALD trial that showed eribulin was non-inferior to taxane when combined with dual HER2 blockade for patients with advanced HER2-positive breast cancer [25].